Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer

Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction. Imatinib is a CYP3A4 inhibitor. A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased doceta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Connolly, Roisin M., Rudek, Michelle A., Garrett-Mayer, Elizabeth, Jeter, Stacie C., Donehower, Michele G., Wright, Laurie A., Zhao, Ming, Fetting, John H., Emens, Leisha A., Stearns, Vered, Davidson, Nancy E., Baker, Sharyn D., Wolff, Antonio C.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111459/
https://ncbi.nlm.nih.gov/pubmed/21350820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1413-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares